BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California. Show more

11085 Torreyana Road, San Diego, CA, 92121, United States

https://www.bioatla.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

12.26M

52 Wk Range

$0.13 - $1.43

Previous Close

$0.17

Open

$0.18

Volume

1,942,740

Day Range

$0.17 - $0.19

Enterprise Value

10.11M

Cash

8.32M

Avg Qtr Burn

-9.881M

Insider Ownership

4.92%

Institutional Own.

20.71%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ozuriftamab vedotin (BA3021) (CAB-ROR2-ADC) Details Squamous cell carcinoma of the head and neck (SCCHN)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evalstotug (BA3071) + Pembrolizumab Details Cancer, Melanoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ozuriftamab vedotin (BA3021) (ROR2-ADC) Details Cancer, Melanoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mecbotamab vedotin (BA3011) (anti-AXL ADC) Details Solid tumor/s, Soft tissue sarcoma, Non-small cell lung carcinoma, Bone sarcoma, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CAB-EpCAM x CAB-CD3 TCE (BA3182) Details Carcinoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evalstotug (BA3071) (CAB anti-CTLA-4 antibody) w/ nivolumab Details Solid tumor/s, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.